Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Revance Therapeutics (RVNC)
NASDAQ:RVNC
RESEARCH TOOLSreports
Revance Therapeutics (RVNC) Stock Price & Analysis
449 Followers
RVNC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.10 - $37.98
Previous Close$13.01
Volume3.25M
Average Volume (3M)1.77M
Market Cap
$1.14B
Enterprise ValueN/A
Total Cash (Recent Filing)$320.00M
Total Debt (Recent Filing)$432.39M
Price to Earnings (P/E)-2.9
Beta1.21
Next Earnings
Nov 07, 2023EPS Estimate
-$0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.54
Shares Outstanding87,955,357
10 Day Avg. Volume4,033,532
30 Day Avg. Volume1,769,799
Standard Deviation0.21
R-Squared0.04
Alpha0.00526
Financial Highlights & Ratios
Price to Book (P/B)-14.51
Price to Sales (P/S)18.99
Price to Cash Flow (P/CF)N/A
P/FCF Ratio65.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$34.13Price Target Upside171.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Revance Therapeutics News
Stock Analysis & Ideas‘Load Up,’ Says Goldman Sachs About These 2 ‘Strong Buy’ Stocks
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RVNC FAQ
What was Revance Therapeutics’s price range in the past 12 months?
Revance Therapeutics lowest stock price was $11.10 and its highest was $37.98 in the past 12 months.
What is Revance Therapeutics’s market cap?
Currently, no data Available
When is Revance Therapeutics’s upcoming earnings report date?
Revance Therapeutics’s upcoming earnings report date is Nov 07, 2023 which is in 42 days.
How were Revance Therapeutics’s earnings last quarter?
Revance Therapeutics released its earnings results on Aug 08, 2023. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.633 by $0.073.
Is Revance Therapeutics overvalued?
According to Wall Street analysts Revance Therapeutics’s price is currently Undervalued.
Does Revance Therapeutics pay dividends?
Revance Therapeutics does not currently pay dividends.
What is Revance Therapeutics’s EPS estimate?
Revance Therapeutics’s EPS estimate is -$0.71.
How many shares outstanding does Revance Therapeutics have?
Revance Therapeutics has 87,955,360 shares outstanding.
What happened to Revance Therapeutics’s price movement after its last earnings report?
Revance Therapeutics reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.633. Following the earnings report the stock price went down -8.049%.
Which hedge fund is a major shareholder of Revance Therapeutics?
Among the largest hedge funds holding Revance Therapeutics’s share is Deerfield Management Company, LP. It holds Revance Therapeutics’s shares valued at 22M.
---
Revance Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.13 (171.95% Upside)
$34.13 (171.95% Upside)
Blogger Sentiment
Neutral
RVNC Sentiment 50%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.3%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.84%
12-Months-Change
Fundamentals
Return on Equity
-2962.17%
Trailing 12-Months
Asset Growth
6.35%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Revance Therapeutics
Revance Therapeutics, Inc. is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.
---
Top 5 ETFs holding RVNC
Vanguard Total Stock Market ETF
$45.01M
Vanguard Health Care ETF
$5.13M
Picton Mahoney Fortified Market Neutral Alternative Fund ETF
$1.47M
Picton Mahoney Fortified Long Short Alternative Fund Trust Units
$592.79K
Vanguard Russell 3000 ETF
$94.34K
Up to five ETFs with an Outperform Smart Score that hold RVNC. The ETFs are listed according to market value of RVNC within the ETF
---